From URPTG to PRAC
What the TGA’s New Market Action Framework Means in Practice
The Australian Therapeutic Goods Administration (TGA) fundamentally reshaped how sponsors manage recalls and other market actions when the Procedure for Recalls, Product Alerts and Product Corrections (PRAC) came into effect on 5 March 2025, and published a revision on 24 February 2026 . This change replaced the long‑standing Uniform Recall Procedure for Therapeutic Goods (URPTG) and applies across medicines, medical devices, biologicals and other therapeutic goods supplied in Australia.
While the TGA has been clear that PRAC is largely a structural rewrite rather than a legislative overhaul, the practical impact for sponsors should not be underestimated. Terminology has changed, process steps have been condensed, and accountability has shifted more squarely onto sponsors’ internal systems and data quality.
For quality and regulatory leaders, PRAC is more than a documentation update. It is a stress test of post‑market surveillance maturity, recall readiness, and governance. Organisations still operating with “URPTG‑era thinking” will find that legacy procedures no longer align cleanly with regulator expectations under PRAC.
What PRAC is – and how it differs from URPTG
At its core, PRAC is the TGA’s guidance for how sponsors must plan, notify, execute and report market actions in Australia. It consolidates what were previously multiple recall and non‑recall pathways under URPTG into a single, more coherent framework.
One of the most visible changes is the shift in terminology. Under URPTG, sponsors navigated multiple categories of “recall” and “non‑recall” actions. PRAC removes this distinction and introduces a single umbrella term: market actions, which are then described by class, type and level. This simplification aims to reduce confusion without changing the underlying risk‑based intent.
Ref: https://www.tga.gov.au/sites/default/files/2025-02/market-action-nomenclature.JPG
PRAC also condenses the recall process itself. What was previously a ten‑step pathway under URPTG is now articulated as a five‑step process, supported by clearer tables, diagrams and standalone templates hosted on the TGA website. This structural clarity is intended to reduce administrative friction, but it also removes some of the procedural “hand‑holding” sponsors relied on in the past.
Key PRAC changes with real operational impact
Several PRAC changes have a direct and practical effect on sponsor operations. The first is reduced TGA verification of sponsor data. Under PRAC, the TGA no longer undertakes extended back‑and‑forth to verify customer lists. Sponsors are expected to submit accurate, complete information upfront to avoid delays. This places greater emphasis on distribution traceability and data governance.
Another significant shift is the clarification and formalisation of the Early Advice process. PRAC provides clearer guidance on when sponsors should contact the TGA about emerging issues, particularly where there may be imminent or significant risk to public health. Transparency has increased, but so has the expectation that sponsors escalate appropriately and early.
PRAC also retains and reinforces reforms introduced in the final URPTG version (v2.4, March 2024), including more flexible reporting requirements and the removal of mandatory two‑week status reports in all cases. While this offers flexibility, it also requires stronger internal judgement about what constitutes appropriate reporting frequency.
Case studies: URPTG vs PRAC in action
Scenario 1: Medical device labelling correction
Under URPTG, a sponsor identifying a minor labelling error often struggled to determine whether the action was a “recall” or “non‑recall”, leading to delays while categories were debated. Under PRAC, the same issue is treated as a market action with a defined class and type, allowing the sponsor to focus on risk assessment and communication rather than terminology. This reduces internal friction and accelerates execution without changing patient safety outcomes.
Scenario 2: Urgent safety issue requiring immediate action
Previously, URPTG processes encouraged sponsors to wait for TGA review before broad customer notification, even in time‑critical scenarios. PRAC explicitly allows – and in some cases expects – Immediate Actions, where customers are notified as soon as possible to prevent harm, with the TGA notified promptly in parallel. This represents a cultural shift towards sponsor‑led urgency and accountability.
Scenario 3: Distribution data integrity
Under URPTG, sponsors sometimes relied on iterative TGA feedback to refine customer lists. Under PRAC, inaccurate or incomplete lists can directly delay TGA notifications to state and territory recall coordinators. Sponsors with fragmented ERP or distribution records have found this change exposes systemic weaknesses that were previously masked.
Practical guidance – what good looks like under PRAC
Strong PRAC compliance starts well before a market action occurs. Organisations should ensure their post‑market surveillance procedures clearly reference PRAC terminology, definitions and triggers, rather than legacy URPTG language. Mixed terminology is a common audit red flag.
Governance frameworks should explicitly define decision‑making authority for Early Advice and Immediate Actions. In practice, this means pre‑agreed escalation thresholds, documented risk criteria, and 24/7 availability of accountable decision‑makers for high‑risk products.
Data readiness is critical. Sponsors should regularly test distribution traceability through mock recalls, ensuring customer lists can be generated quickly and accurately. PRAC’s reduced regulator verification means internal errors now translate directly into regulatory delays.
PRAC readiness checklist (indicative):
- Clear mapping of URPTG procedures to PRAC terminology
- Defined Early Advice and Immediate Action triggers
- Tested customer and distribution data integrity
- Standalone access to current TGA PRAC templates
- Training for quality, regulatory and supply chain teams
Embedding PRAC into quality management systems (QMS) also supports alignment with international expectations, including Medical Device Single Audit Program (MDSAP) audits, which have updated references from URPTG to PRAC.
Pitfalls to avoid
- Retaining URPTG language in procedures, causing confusion during incidents.
- Treating PRAC as “just a rewrite” and not retraining staff.
- Weak Early Advice escalation pathways.
- Incomplete or outdated customer distribution lists.
- Over‑reporting or under‑reporting due to misjudged flexibility.
- Delayed decision‑making in Immediate Action scenarios.
- Poor alignment between global recall SOPs and Australian PRAC requirements.
- Assuming the TGA will correct sponsor data errors.
- Lack of documented recall governance and authority.
- Infrequent or unrealistic mock recall testing.
Moving from compliance to confidence
PRAC represents a deliberate shift by the TGA towards clarity, efficiency and sponsor accountability. While the underlying public health intent remains unchanged from URPTG, the way sponsors are expected to operate has evolved.
Organisations that proactively align their systems, data and governance to PRAC are finding not only smoother regulatory interactions, but also stronger internal confidence when market actions are required.
Next steps for sponsors:
- Review and update recall and post‑market SOPs
- Retrain cross‑functional teams on PRAC concepts
- Conduct PRAC‑aligned mock recalls
- Stress‑test Early Advice and Immediate Action pathways
- Treat PRAC as an operational capability, not a document update
PharmOut services & training
PharmOut supports sponsors across medicines, medical devices and biologicals to operationalise PRAC within existing quality systems. Our services include PRAC gap assessments, procedure remediation, mock recall facilitation, and targeted training for quality and regulatory teams. We focus on building practical, audit‑ready systems that work under real‑world pressure, not just on paper.
Explore elearning and public courses via onlinegmptraining.com, or contact us via the website or via email to tailor workshops to your needs.
Frequently Asked Questions (FAQ)
The Procedure for Recalls, Product Alerts and Product Corrections (PRAC) replaced the Uniform Recall Procedure for Therapeutic Goods (URPTG) to simplify terminology, streamline processes, and improve clarity for sponsors conducting market actions in Australia.
The fundamental intent of the process has not changed, but PRAC condenses the pathway from ten steps to five and removes unnecessary complexity, making it easier for sponsors to act quickly and consistently.
PRAC replaces the previous “recall” and “non‑recall” distinction with a single term—market action—which is then defined by class, type and level based on risk and impact.
Immediate Actions allow sponsors to notify customers as soon as possible, before TGA review, where there is an imminent or significant risk to public health. This reflects a shift towards faster, sponsor‑led risk management.
Under PRAC, the TGA no longer routinely verifies customer lists. Sponsors must ensure their distribution data is accurate and readily available, as errors can directly delay regulatory communications and market actions.
